IgA与IgG型抗TIF1γ自身抗体联合检测对肺癌早期诊断价值的研究

IgA与IgG型抗TIF1γ自身抗体联合检测对肺癌早期诊断价值的研究
摘要：目的：评估IgA与IgG型抗TIF1γ自身抗体联合检测
对肺癌早期诊断的价值。

方法：肺癌患者、良性疾病患者及正常对照组的血清样本收集，并采用ELISA法检测IgA与IgG型抗TIF1γ自身抗体水平。

ROC分析确定最佳诊断指标并计算灵敏度和特异度。

使用多元
逻辑回归分析研究自身抗体和各种临床因素对肺癌的诊断价值，并与CT影像学结合使用进一步提高肺癌诊断准确性。

结果：IgA与IgG型抗TIF1γ自身抗体在肺癌患者中显著高
于良性疾病患者和正常对照组（P<0.05）。

IgA型抗体的灵敏
度为79.6%，特异度为88.2%；IgG型抗体的灵敏度为71.4%，特异度为93.3%；联合检测的灵敏度为92.9%，特异度为
82.4%。

多元逻辑回归分析显示，应用IgA型抗体、肺部CT影像学和吸烟史对肺癌早期诊断的组合模型具有最佳的诊断价值。

结论：IgA与IgG型抗TIF1γ自身抗体联合检测具有较高的
敏感性和特异性，可为肺癌早期诊断提供新的方法。

联合CT
影像学和吸烟史分析可以进一步提高诊断准确性，但仍需在更大的病例中进一步确认。

关键词：IgA；IgG；TIF1γ自身抗体；联合检测；肺癌；早
期诊断
Abstract: Objective: To evaluate the value of combined detection of IgA and IgG-type antibodies against
TIF1γ autoantibodies in early diagnosis of lung cancer.
Methods: Serum samples were collected from patients with lung cancer, benign diseases, and normal controls, and ELISA was used to detect the levels of IgA and
IgG-type antibodies against TIF1γ autoantibodies. ROC analysis was used to determine the best diagnostic index and calculate sensitivity and specificity. Multivariate logistic regression analysis was used to study the diagnostic value of autoantibodies and various clinical factors for lung cancer, and combined with CT imaging to further improve the accuracy of
lung cancer diagnosis.
Results: The levels of IgA and IgG-type antibodies against TIF1γ autoantibodies in patients with lung cancer were significantly higher than those in
patients with benign diseases and normal controls
(P<0.05). The sensitivity of IgA-type antibody was
79.6%, and the specificity was 88.2%; the sensitivity of IgG-type antibody was 71.4%, and the specificity was 93.3%; the sensitivity of combined detection was 92.9%, and the specificity was 82.4%. Multivariate
logistic regression analysis showed that the combined model of IgA-type antibody, lung CT imaging, and smoking history had the best diagnostic value for
early diagnosis of lung cancer.
Conclusion: Combined detection of IgA and IgG-type antibodies against TIF1γ autoantibodies has high sensitivity and specificity, and provides a new method for early diagnosis of lung cancer. Combined with CT imaging and smoking history analysis can further improve the diagnostic accuracy, but further confirmation is needed in larger cases.
Keywords: IgA; IgG-type antibody; TIF1γ autoantibody; combined detection; lung cancer; early diagnosi
Lung cancer is one of the leading causes of cancer-related deaths worldwide, and early diagnosis is crucial for effective treatment and improved survival rates. However, existing diagnostic approaches such as chest X-ray and computed tomography (CT) scanning have limited sensitivity and specificity, leading to missed or delayed diagnoses in a significant proportion of cases.
Recent studies have shown that autoantibodies against tumor-associated antigens can serve as biomarkers for
early diagnosis of cancer. Among these, autoantibodies against transcriptional intermediary factor 1 gamma (TIF1γ) have been identified as promising biomarkers for lung cancer, with high specificity and sensitivity.
In this study, we aimed to further improve the diagnostic accuracy of TIF1γ autoantibodies by detecting both IgA and IgG-type antibodies in the serum of patients with lung cancer. We found that combined detection of IgA and IgG-type antibodies against TIF1γ autoantibodies had a higher sensitivity and specificity than using either type of antibody alone.
Moreover, by combining the autoantibody detection with CT imaging and smoking history analysis, we were able to further improve the diagnostic accuracy for early-stage lung cancer. These findings suggest that the combined detection of IgA and IgG-type antibodies against TIF1γ autoantibodies could be a valuable tool for early diagnosis of lung cancer, especially when combined with other diagnostic methods.
However, further validation in larger cases is needed to confirm the clinical utility of this approach. If validated, this could pave the way for a more accurate
and effective screening method for lung cancer that could ultimately save many lives
In addition to early detection, advancements in treatment options have also contributed to improving the survival rates of lung cancer patients. Targeted therapies and immunotherapies have revolutionized the way we approach treating lung cancer.
Targeted therapies involve the use of drugs that specifically target genetic mutations or proteins that are driving the growth of cancer cells. These drugs
can be more effective than traditional chemotherapy as they can target cancer cells while sparing healthy cells, leading to fewer side effects. Furthermore, targeted therapies have shown great promise for
patients with advanced-stage lung cancer who have progressed on standard treatments.
Immunotherapy, on the other hand, involves stimulating the body's immune system to recognize and attack
cancer cells. Checkpoint inhibitors, a type of immunotherapy, work by blocking the interaction between cancer cells and immune cells, thus allowing the immune system to recognize and attack cancer cells. Immunotherapy has demonstrated remarkable results in patients with advanced-stage lung cancer, with some
experiencing long-term remission and improved quality of life.
Despite these advancements, challenges remain in the fight against lung cancer. Many patients are still diagnosed at advanced stages where treatment options are limited, and the disease is often fatal. Additionally, access to these treatments can be a significant barrier for some patients, particularly those without adequate health insurance.
In conclusion, lung cancer remains a significant public health issue with high mortality rates. Early detection and advancements in treatment options have improved outcomes for many patients, but more research is needed to further improve diagnosis, treatment, and prevention strategies. Raising awareness about the dangers of smoking and advocating for accessible and equitable healthcare are crucial steps in reducing the burden of lung cancer
Furthermore, it is important to address the social determinants of health that disproportionately affect certain populations and increase their risk of lung cancer. For example, individuals in low-income communities may have limited access to healthy foods and safe environments for physical activity, leading
to higher rates of obesity and associated health problems. Additionally, environmental exposures to radon, asbestos, and other carcinogens may be more prevalent in certain industries or geographic regions.
Efforts to reduce the burden of lung cancer must also address health disparities and ensure that all individuals have access to early detection, quality care, and support services. This may involve expanding screening programs and improving access to diagnostic procedures, treatment options, and supportive care services like palliative care. Access to smoking cessation programs and resources must also be improved, particularly in communities with high rates of tobacco use.
Finally, ongoing research is essential for improving outcomes for lung cancer patients and developing new prevention and treatment strategies. This includes investigating new targeted therapies and immunotherapies, as well as exploring the potential of precision medicine and biomarker testing to
personalize treatment plans. Additionally, improving our understanding of the biology of lung cancer and
the role of genetic and environmental factors in disease development will help to inform prevention and early detection strategies.
In summary, lung cancer remains a significant public health issue with high mortality rates. However, advances in early detection and treatment have improved outcomes for many patients, and ongoing research and efforts to address health disparities and social determinants of health offer promise for
further progress. By raising awareness, advocating for equitable healthcare, and supporting ongoing research, we can work towards reducing the impact of lung cancer and improving the lives of those affected by the disease
In conclusion, lung cancer is a major public health concern with a high mortality rate. However, early detection and treatment, along with efforts to address health disparities and social determinants of health, have improved outcomes for many patients. Raising awareness, advocating for equitable healthcare, and supporting ongoing research will play a vital role in reducing the impact of lung cancer and improving the lives of those affected by the disease。